Tobacco addiction and pharmacogenetics of nicotine metabolism.
This paper presents a brief overview of several components of tobacco addiction, including: 1) the epidemiology of smoking in the United States and elsewhere around the world; 2) implications of the pharmacogenetic study of nicotine metabolism for understanding tobacco addiction and its treatment; 3) the use of the twin design as an example of one strategy to understand the contribution of genetic and environmental factors to the pharmacokinetics of nicotine metabolism; 4) results from recent genomic studies of tobacco addiction in adults; and 5) a discussion of progress (past and future) toward the development of a comprehensive understanding of the pharmacogenetics of tobacco addiction and its treatment.
Swan
Gary E
GE
Center for Health Sciences, SRI International, Menlo Park, California 94025, USA. gary.swan@sri.com
Lessov-Schlaggar
Christina N
CN
D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics; D065637:Cytochrome P-450 CYP2A6; D004777:Environment; D056726:Genetic Association Studies; D006801:Humans; D009538:Nicotine / Q000378:metabolism*; D010597:Pharmacogenetics / Q000379:methods*; D012907:Smoking / Q000235:genetics; D016540:Smoking Cessation / Q000379:methods; D014029:Tobacco Use Disorder / Q000453:epidemiology / Q000235:genetics* / Q000628:therapy; D018433:Twin Studies as Topic; D014481:United States / Q000453:epidemiology
D009538:Nicotine; D001189:Aryl Hydrocarbon Hydroxylases; D065637:Cytochrome P-450 CYP2A6